Your Location：
Home >
Browse articles >
Differentiation and Treatment of Vulnerable Atherosclerotic Plaque Based on "Collateral Disease" Theory
Updated：2026-07-16
Previous|Next

    • Differentiation and Treatment of Vulnerable Atherosclerotic Plaque Based on "Collateral Disease" Theory

      Enhanced Publication
    • LU Zhen , OU Xinyan , ZHOU Muhan , WANG Jianmei , JING Haoran , TAO Weiwei , LI Yunlun , PEI Ke
    • Chinese Journal of Experimental Traditional Medical Formulae Vol. 32, Issue 16, Pages: 275-284(2026)

    • DOI： 10.13422/j.cnki.syfjx.20252292     

      CLC：

    • Revised：2025-07-01 ，

      Accepted：24 July 2025 ，

    Scan QR Code

  •  
  •  

  • AI Introduction

  • Full Text(HTML)

  • Figs( 1 ) Tabs( 2 )

  • References

  • Publication Info

  • Metrics

137

Views

114

Downloads

0

CSCD

Alert me when the article has been cited
Submit
Tools
  • BibTeXDownload
  • EndnoteDownload
  • RefMan Download
  • NoteExpressDownload
  • NoteFirstDownload

Related Articles

Iron Homeostasis Imbalance Promotes Atherosclerosis and Therapeutic Mechanisms of Traditional Chinese Medicine
Mechanism of Huoxin Pills in Stabilizing Atherosclerotic Vulnerable Plaque Based on Network Pharmacology and Metabolomics
Effect and Molecular Mechanisms of Danlou Tablet on Hepatic Lipid Deposition in ApoE-/- Atherosclerotic Mice Through Regulation of SIRT6/CREB/Nor1 Signaling Pathway-mediated Autophagy
Mechanism of Danlou Tablets in Ameliorating Hepatic Lipid Deposition by Regulating circCRIM1/miR-342-3p/SOX6-mediated Fatty Acid Synthesis
Clinical and Mechanistic Research Progress on Classical Traditional Chinese Medicine Formulas in Treatment of Chronic Heart Failure

Related Author

LI Yunlun
WANG Maohong
XIONG Jianhua
ZHANG Hao
YAN Xiaohong
WAN Qiang
XIANG Jiao
LUO Jieying

Related Institution

Jiangxi University of Chinese Medicine
The Affiliated Hospital of Jiangxi University of Chinese Medicine
School of Chinese Materia Medica，Guangzhou University of Chinese Medicine
Baiyunshan Pharmaceutical General Factory， Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.
Guangzhou Caizhilin Pharmaceutical Co. Ltd.